Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain’s CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease
Exclusive worldwide license adds a structurally distinct SGK1 inhibitor scaffold to Thryv’s portfolio, with claims spanning neurodegenerative and…